Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.
On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...
Dr. Marwan G. Fakih discussed the FDA approval of Lumakras with Vectibix for third-line treatment of KRAS G12C-mutated ...
Amgen is also scheduled to report new data from the CodeBreak-101 study of the drug, in combination with its EGFR inhibitor Vectibix (panitumumab), in KRAS-mutated colorectal cancer at the ESMO ...
Before 2009, Amgen's Vectibix (panitumumab), an inhibitor of epidermal growth factor receptor approved for colon cancer, and Humira (adalimumab), a TNF-α inhibitor marketed by Abbott Laboratories ...
Sales of the firm's bispecific T-cell engager Blincyto increased more than 50 percent from the fourth quarter of 2023 to 2024.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and ...
Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback